Sector Gamma AS Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sector Gamma AS trimmed its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 39.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 32,092 shares of the biopharmaceutical company’s stock after selling 20,876 shares during the quarter. Alnylam Pharmaceuticals makes up 1.5% of Sector Gamma AS’s investment portfolio, making the stock its 23rd largest position. Sector Gamma AS’s holdings in Alnylam Pharmaceuticals were worth $6,143,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quent Capital LLC lifted its holdings in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $38,000. GAMMA Investing LLC purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $52,000. Lindbrook Capital LLC lifted its stake in shares of Alnylam Pharmaceuticals by 37.2% in the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 100 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 52.4% in the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 311 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded down $0.40 during trading on Friday, reaching $143.31. The company’s stock had a trading volume of 479,139 shares, compared to its average volume of 467,891. The company has a market capitalization of $18.05 billion, a price-to-earnings ratio of -40.26 and a beta of 0.39. The stock’s 50-day moving average price is $150.21 and its 200 day moving average price is $165.79. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.68) EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ALNY. Chardan Capital decreased their price target on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday, February 1st. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 13th. Finally, Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research note on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $215.88.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.